Skip to main content
. Author manuscript; available in PMC: 2019 Aug 21.
Published in final edited form as: Immunity. 2018 Aug 14;49(2):225–234.e4. doi: 10.1016/j.immuni.2018.07.013

Figure 5. Nazo encodes a dSTING-regulated antiviral effector.

Figure 5.

(A) Schematic representation and sequence identity between Nazo, CG3740 and human C19orf12.

(B – E) Stable cell lines expressing Nazo or CG3740 under the control of the CuSO4 inducible promoter were established and infected with DCV (B and C), CrPV (D) or FHV (E). The cell lysates prepared 24h post-infection were analyzed by immunoblot using the indicated antibodies. Data are representative of at least two independent experiments.

(F) Expression of both dSTING and Nazo was monitored by RT-qPCR in cells silenced for either dSTING or Nazo. Data are representative of 2 independent experiments, each containing 6 biological replicates.

(G) The impact of short dSTING overexpression on DCV replication was monitored in cells treated with a control dsRNA (GFP) or silenced for Nazo. The qRT-PCR results shown are the average of two independent experiments (three biological replicates per experiment).

(H) Nazo-V5 overexpressing cells were treated with the indicated dsRNAs, infected with DCV and viral replication was monitored by immunoblot. Data are a representative from at least two independent experiments. Statistics are the same as in Figure 1. See also Figure S4D,E.